Search clinical trials for: ER OROS paliperidone and Olanzapine

Total 1316 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Xian-Janssen Pharmaceutical Ltd.

Completed

A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia

Acute Schizophrenia

China
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

Schizophrenia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function

Schizophrenia | Renal Impairment
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

Schizophrenia
Watson Pharmaceuticals

Completed

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) (DRIVE)

Anemia, Iron-Deficiency | Hemodialysis | Kidney Failure, Chronic

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Bioequivalence Study of 15 mg ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone

Schizophrenia
Janssen-Cilag International NV

Completed

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Schizophrenia

Spain, Argentina, Romania, South Africa, Turkey, Greece, Lithuania, Slovakia, Latvia, Estonia, France, Egypt, Lebanon, Jordan
Beijing HuiLongGuan Hospital

Completed

The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Bipolar Disorder

United States, China, Germany, Bulgaria, Costa Rica, France, India, Malaysia, Panama, Poland, Romania, Russian Federation, Serbia, South Africa, Turkey, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone

Schizophrenia
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone

Schizophrenia
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia | Bipolar Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

Epilepsy | Schizophrenia
Johnson & Johnson Taiwan Ltd

Completed

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag S.p.A.

Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

Schizophrenia
Janssen Research & Development, LLC

Completed

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Psychotic Disorders | Schizophrenia | Schizophrenic Disorders | Dementia Praecox

United States, Belgium, Poland, Bulgaria, India, Romania, Russian Federation, Ukraine, Korea, Republic of, Estonia, Finland
Janssen Pharmaceutica

Completed

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag B.V.

Completed

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

Schizophrenia

Netherlands
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder

United States, India, Malaysia, Romania, Korea, Republic of, Philippines
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Schizophrenia

United States, India, Romania, Russian Federation, Ukraine
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Schizophrenia

Brazil
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Bipolar Disorder | Mania | Affective Psychosis, Bipolar
Indiana University School of Medicine
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Autism

United States
National Taiwan University Hospital

Unknown

A Pharmacokinetic Study of Paliperidone ER

Schizophrenia | Schizoaffective Disorder

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Schizophrenia

United States, Taiwan, India
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Janssen-Cilag, S.A.

Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia (PERFLEX)

Schizophrenia

Colombia, Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

Schizophrenia
Janssen-Cilag International NV

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

Schizophrenia

France, United Kingdom, Belgium, Germany, Spain, Portugal, Bulgaria, Serbia, Switzerland, Israel, Finland, Greece, Sweden, Russian Federation, Netherlands, Denmark, Hungary, Lithuania, Latvia, Croatia, Turkey, Poland
Chonbuk National University Hospital
Janssen Korea, Ltd., Korea

Completed

Efficacy and Safety of Paliperidone ER in First Episode Psychosis

First Episode Psychosis

Korea, Republic of

3

Subscribe